Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience
Background: Adjuvant therapy is used to reduce the risk of hepatocellular carcinoma (HCC) recurrence and improve patient prognosis. Exploration of treatment strategies that are both efficacious and safe has been extensively performed in the recent years. Although donafenib has demonstrated good effi...
保存先:
| 主要な著者: | , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publishing
2024-06-01
|
| シリーズ: | Therapeutic Advances in Medical Oncology |
| オンライン･アクセス: | https://doi.org/10.1177/17588359241258394 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|